Crescita Therapeutics Inc. (CTX)
Market Closed
6 Jun, 20:00
TSX TSX Primary CA$
0. 47
-0.07
-12.96%
CA$
8.7M Market Cap
- P/E Ratio
0% Div Yield
109,700 Volume
0 Eps
CA$ 0.54
Previous Close Day Range
0.45 0.52
Year Range
0.41 0.69
Earnings results expected in 58 days
Summary
CTX closed yesterday lower at CA$0.47, a decrease of 12.96% from Thursday's close, completing a monthly decrease of -2.08% or CA$0.01. Over the past 12 months, CTX stock lost -20.34%.
CTX is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2025, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on TSX (CAD).
Want to track CTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CTX Chart
Loading, please wait...
Crescita Therapeutics Inc. Dividends
CTX is not paying dividends to its shareholders.
Crescita Therapeutics Inc. Earnings
| 5 Aug 2025 (58 Days) Date | | - Cons. EPS | - EPS |
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
CTX is not paying dividends to its shareholders.
| 5 Aug 2025 (58 Days) Date | | - Cons. EPS | - EPS |
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
Crescita Therapeutics Inc. (CTX) FAQ
What is the stock price today?
The current price is CA$0.47.
On which exchange is it traded?
Crescita Therapeutics Inc. is listed on TSX.
What is its stock symbol?
The ticker symbol is CTX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.7M.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Aug 05, 2025.
Has Crescita Therapeutics Inc. ever had a stock split?
No, there has never been a stock split.
Crescita Therapeutics Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Serge Verreault B.A., M.B.A. CEO | TSX Exchange | CA2258471028 ISIN |
| CA Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Crescita Therapeutics Inc., established in 2016 and based in Laval, Canada, is a dermatology company that specializes in providing both non-prescription skincare products and prescription drug products. With a presence in Canada, the United States, and other international markets, Crescita operates across three main segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company is known for owning proprietary platform technologies such as Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel, which facilitate the development of topical treatments containing cannabis and hemp. Through its diverse portfolio and strategic partnerships with entities like Cantabria Labs Inc. and Taro Pharmaceuticals Inc., Crescita Therapeutics aims to advance dermatological care and meet various skin health needs.
Products and Services
Prescription Products:
- Pliaglis: A topical local anesthetic cream designed to provide dermal analgesia on intact skin in preparation for superficial dermatological procedures.
- CTX-101: A Phase III topical formulation combining a corticosteroid with MMPE technology to address plaque psoriasis.
- CTX-102: A Phase I topical formulation using MMPE technology aimed at treating an undisclosed dermatological skin condition.
- Dermatology Products in Pre-Clinical Formulation: Utilizes MMPE technology for the prescription treatment of various skin diseases.
Non-Prescription Portfolio:
- Laboratoire Dr Renaud: Offers dermocosmetic products such as facial creams, cleansers, exfoliants, masks, serums, and suncare, targeting mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea.
- Pro-Derm and Alyria: Provides medical aesthetics products for non-invasive and minimally invasive procedures or skincare treatments.
- NCTF Boost 135 HA: A skin revitalization solution distributed by Crescita Therapeutics.
- Obagi Medical Products: Offers a range of skincare products focused on minimizing the appearance of premature skin aging, skin damage, acne, sun damage, and hyperpigmentation.
- ART FILLER: A line of hyaluronic acid-based dermal fillers aimed at enhancing and restoring facial volume and contours.
Contact Information
Address: 2805 Place Louis-R Renaud
Phone: 800 361 0352
Website: https://www.crescitatherapeutics.com
2025 © Marketlog. All Rights Reserved.
